The Vanguard Group 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:13 pm Purchase | 2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC | The Vanguard Group | 5,069,625 5.770% | 573,309 (+12.75%) | Filing |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC | The Vanguard Group | 4,496,316 5.470% | 894,019 (+24.82%) | Filing |
| 2022-02-10 08:32 am Purchase | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | The Vanguard Group | 3,602,297 5.020% | 3,602,297 (New Position) | Filing |